ITI Mutual Fund · #149268
ITI Pharma and Healthcare Fund - Direct Plan - Growth Option
Equity · Sectoral/ Thematic · Direct · Growth
Direct TER: 0.89% · as of
5-year NAV · change the window using the controls in the rolling-returns card below ↓
2021-11-11 → 2026-10-22
Latest NAV
₹18.4740
as of 2026-10-22 · -0.09% vs 2026-10-21
Earliest NAV in archive
2021-11-11
AMFI archive begins Apr 2006
Trailing CAGR vs assigned benchmark
| Window | Scheme CAGR | Benchmark CAGR | Excess | Period |
|---|---|---|---|---|
| 1y | +2.90% | — | — | 2025-10-23 → today · 1.0y |
| 3y | +18.18% | — | — | 2023-10-23 → today · 3.0y |
Benchmark assignment is mapped by category and sub-category from public sources. "Since inception (in archive)" uses the earliest NAV in the AMFI archive (April 2006 onward).
Rolling 1-year returns distribution · 971 daily entry points · last 5 years
Imagine buying this fund on any day in this period and holding for exactly one year. Each bar counts how often that ended with a given return: green bars made money, red bars lost money even after a full year. Taller bar = more common outcome.
Median 1y return
+15.7%
Mean 1y return
+19.1%
Best / worst 1y
+61.9% / -9.3%
Windows positive
78%
Longer rolling windows · annualised
Same idea over longer holding periods. Returns are CAGR (annualised) so they're directly comparable to the trailing-CAGR table above.
| Period | Median | Mean | Worst | Best | % positive | Windows |
|---|---|---|---|---|---|---|
| 3y rolling | +21.4% | +21.8% | +17.4% | +27.5% | 100% | 480 |
Beat-benchmark consistency · vs assigned benchmark, across overlapping windows
Of all the rolling windows we observed, how often did this fund's return exceed the benchmark's over the same window. A higher fraction means more consistent outperformance, but says nothing about future windows.
| Period | Windows beat | Total windows | % beat | Avg excess (annualised) |
|---|---|---|---|---|
| 1y rolling | 277 | 591 | 47% | -0.4% |
| 3y rolling | 47 | 100 | 47% | -0.1% |
Monthly returns · since inception (Nov 2021)
How each calendar month went: green months gained, red months lost. Deeper colour = bigger move.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -6.3 | +5.5 | -4.6 | +8.3 | +3.7 | +5.3 | +3.6 | +2.9 | -4.1 | -5.1 | · | · | +8.3 |
| 2025 | -8.8 | -7.9 | +7.4 | +1.6 | +0.4 | +3.4 | +2.2 | -4.4 | -1.1 | +3.4 | -0.6 | -2.9 | -8.2 |
| 2024 | +5.7 | +3.6 | +0.6 | +0.9 | -2.6 | +6.9 | +10.7 | +6.0 | +2.6 | +0.5 | +0.8 | +2.1 | +44.0 |
| 2023 | -1.4 | -4.4 | +1.7 | +4.4 | +3.2 | +7.2 | +6.4 | +0.6 | +1.5 | -3.6 | +10.6 | +4.8 | +34.4 |
| 2022 | -5.5 | -5.4 | +4.3 | -0.1 | -6.6 | -2.3 | +6.8 | +0.0 | +2.3 | +3.8 | +0.4 | -3.6 | -6.7 |
| 2021 | · | · | · | · | · | · | · | · | · | · | · | +4.2 | +4.2 |
| Avg | -3.3 | -1.7 | +1.9 | +3.0 | -0.4 | +4.1 | +6.0 | +1.0 | +0.3 | +1.0 | +2.8 | +0.9 | +15.9 |
All values in %. Each cell compares the last NAV of the month with the last NAV of the month before. The latest month is month-to-date; the Year column compounds the months shown on that row. The Avg row is the plain average of each column across the years shown (4 complete calendar years in the last column); the running month is left out of it.
Portfolio mix · asset class breakdown as of 2026-09-30
Size axis (Style Box) · Large / Mid / Small split of latest disclosed holdings
Per AMFI's semi-annual Categorisation of Stocks (top 100 = Large, 101-250 = Mid, 251+ = Small).
- Large Cap 35.9%
- Mid Cap 40.4%
- Small Cap 23.0%
- Cash & Equivalents 0.7%
Index overlap
· vs · share of this fund's AUM that sits in stocks the index also includesNo holdings data yet for this fund.
Top stocks held · 37 holdings as of 2026-09-30 See changes vs previous snapshot →
| Stock | Sector | % of fund |
|---|---|---|
| Sun Pharmaceutical Industries Limited | Pharmaceuticals & Biotechnology | 11.96% |
| Divi's Laboratories Limited | Pharmaceuticals & Biotechnology | 9.51% |
| Apollo Hospitals Enterprise Limited | Healthcare Services | 5.45% |
| Dr. Reddy's Laboratories Limited | Pharmaceuticals & Biotechnology | 4.78% |
| Torrent Pharmaceuticals Limited | Pharmaceuticals & Biotechnology | 4.78% |
| Max Healthcare Institute Limited | Healthcare Services | 4.49% |
| Cipla Limited | Pharmaceuticals & Biotechnology | 4.19% |
| Laurus Labs Limited | Pharmaceuticals & Biotechnology | 4.02% |
| Aurobindo Pharma Limited | Pharmaceuticals & Biotechnology | 4.01% |
| Mankind Pharma Limited | Pharmaceuticals & Biotechnology | 3.78% |
| Cohance Lifesciences Limited | Pharmaceuticals & Biotechnology | 3.14% |
| Alkem Laboratories Limited | Pharmaceuticals & Biotechnology | 3.09% |
| Neuland Laboratories Limited | Pharmaceuticals & Biotechnology | 3.07% |
| Global Health Limited | Healthcare Services | 2.85% |
| Fortis Healthcare Limited | Healthcare Services | 2.77% |
| Abbott India Limited | Pharmaceuticals & Biotechnology | 2.14% |
| Lupin Limited | Pharmaceuticals & Biotechnology | 2.04% |
| IPCA Laboratories Limited | Pharmaceuticals & Biotechnology | 1.94% |
| Sai Life Sciences Limited | Pharmaceuticals & Biotechnology | 1.87% |
| Shilpa Medicare Limited | Pharmaceuticals & Biotechnology | 1.61% |
Sector mix
- Healthcare 97.8%
- Consumer Durables 1.2%
- Chemicals 0.9%
Risk metrics, trailing 3y (734 matched daily returns, 2023-10-25 → 2026-10-22)
Calmar
+1.06
CAGR / |max DD| in window
Risk-free rate assumed 6.0% annualised. Benchmark = Nifty Healthcare Index (assigned by category mapping).
Factual data only. No investment advice or recommendation. Read the scheme document and consult a SEBI-registered Investment Adviser for personalised guidance.